Becton Dickinson and Company (BDX) Stock
NYSEBDX has an Alpha Score of 41 out of 100 (weak), computed on Nov 2, 2026 from 3 of 4 sub-scores. 27 members of Congress disclosed 52 trades in BDX since 2013: 25 purchases and 27 sales, most recently Thomas H. Kean (sale, May 21, 2026). 3 of the hedge funds AlphaScala tracks reported BDX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $17.98M. Company insiders reported 0 open-market buys and 5 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 56.5 and its net margin 4.5% (key statistics as of Oct 29, 2026).
What is BDX's Alpha Score?
How it works →Alpha Score of 41 reflects weak overall profile with strong momentum, poor value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 2, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Becton Dickinson and Company (BDX)?
Most recent: Thomas H. Kean (sale, May 21, 2026); records start Apr 16, 2013.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Tom Kean Jr. R-NJ · House | 2026-05-21 | sale | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Kevin Hern R-OK · House | 2026-03-17 | sale | $15k – $50k |
| Lisa McClain R-MI · House | 2025-06-24 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-17 | purchase | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-05-15 | purchase | $1k – $15k |
| Tom Kean Jr. R-NJ · House | 2025-05-13 | purchase | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-04-08 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded BDX, with filing lags →Which hedge funds own BDX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 119K | $17.98M | -86% |
| Marshall Wace | 98K | $14.80M | -94% |
| Bridgewater Associates Ray Dalio | 9K | $1.42M | -1% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Becton Dickinson and Company insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 26, 26 | Feld Michael | EVP, Chief Revenue Officer | SELL | 76 | $15K |
| Sep 28, 26 | Feld Michael | EVP, Chief Revenue Officer | SELL | 76 | $14K |
| Aug 26, 26 | Feld Michael | EVP, Chief Revenue Officer | SELL | 165 | $31K |
| Aug 13, 26 | Polen Thomas E Jr | Chairman, CEO and President | SELL | 4.2K | $768K |
| Aug 11, 26 | Goette Roland | EVP and President, EMEA | SELL | 2.4K | $441K |
| Jul 27, 26 | Feld Michael | EVP, Chief Revenue Officer | SELL | 75 | $12K |
| Mar 26, 26 | Feld Michael | EVP, Chief Revenue Officer | SELL | 75 | $12K |
| Feb 26, 26 | Feld Michael | EVP, Chief Revenue Officer | SELL | 75 | $14K |
| Feb 18, 26 | Scott Bertram L | Director | SELL | 953 | $174K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are BDX's key statistics?
Key statistics as of Oct 29, 2026
How does BDX's valuation compare with the Healthcare sector?
| Metric | BDX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 56.5 | 28.8 | 111 |
| Net margin | 4.52% | 3.66% | 168 |
| Return on equity | 3.80% | 3.80% | 191 |
| Dividend yield (payers) | 1.59% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 8, 2026). P/E excludes loss-making companies.
BDX price chart
Powered by TradingViewWhat does Becton Dickinson and Company do?
Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad portfolio of medical supplies, devices, laboratory equipment, and diagnostic products. It serves healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical companies, and the general public worldwide. Key segments include BD Medical, offering peripheral IV and advanced catheters, vascular access technologies, infusion therapy systems, prefillable drug delivery, and sharps disposal; BD Life Sciences, providing specimen collection, blood culturing, molecular testing, flow cytometry, and diagnostic reagents; and BD Interventional, featuring hernia repair, surgical infection prevention, peripheral intervention, urology, and critical care products. Following its spinoff, revenue derives primarily from BD Medical Essentials, Interventional, Connected Care, and Biopharma segments, with significant international operations. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company plays a vital role in advancing medical discovery, diagnostics, and care delivery across the healthcare sector.